# A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62

> **NCT05409027** · PHASE1 · COMPLETED · sponsor: **Sparrow Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus in Obese
- Obesity
- Type2Diabetes

## Interventions

- **DRUG:** SPI-62
- **DRUG:** Cortisone-d8

## Key facts

- **NCT ID:** NCT05409027
- **Lead sponsor:** Sparrow Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-23
- **Primary completion:** 2022-03-10
- **Final completion:** 2024-02-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05409027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05409027, "A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05409027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*